 HOUSTON, Sept. 20, 2021 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced its inclusion in the FTSE Global Micro Cap Index. Salarius inclusion in the FTSE index will be effective after the U.S. market opens today, Monday, September 20, 2021. 